Why the study?
To evaluate the effect of mavacamten on echocardiographic parameters and cardiac biomarkers in patients with hypertrophic cardiomyopathy.
Does mavacamten improve echocardiographic parameters and cardiac biomarkers in patients with hypertrophic cardiomyopathy?
Comparison
Mavacamten therapy
Design
Systematic review and meta-analysis
Authors
Loading...
Supports mavacamten in obstructive HCM for diastolic and biomarker gains; extends trial data via pooled surrogates.
Does mavacamten improve echocardiographic parameters and cardiac biomarkers in patients with hypertrophic cardiomyopathy?
Mavacamten significantly improves surrogate echocardiographic and biomarker profiles in patients with hypertrophic cardiomyopathy, particularly the obstructive subtype.
Otmani et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: